Gemcitabine and Taxane Combinations in Non–Small-Cell Lung Cancer
- 1 December 2000
- journal article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 2, S15-S21
- https://doi.org/10.3816/clc.2000.s.009
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)Lung Cancer, 2000
- Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2000
- A phase I–II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patientsAnnals of Oncology, 2000
- Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II TrialJournal of Clinical Oncology, 1999
- Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.Journal of Clinical Oncology, 1998
- Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II studyAnnals of Oncology, 1998
- Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.Journal of Clinical Oncology, 1998